WuXi Biologics (Cayman) Inc.
WXIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19 | $17 | $15 | $10 |
| % Growth | 9.6% | 11.6% | 48.4% | – |
| Cost of Goods Sold | $11 | $10 | $9 | $5 |
| Gross Profit | $8 | $7 | $7 | $5 |
| % Margin | 41% | 40.1% | 44% | 46.9% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $2 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $3 | $2 | $2 | $2 |
| Operating Income | $5 | $4 | $4 | $3 |
| % Margin | 26.6% | 26.1% | 28.4% | 31% |
| Other Income/Exp. Net | -$0 | -$0 | $1 | $1 |
| Pre-Tax Income | $5 | $4 | $5 | $4 |
| Tax Expense | $1 | $1 | $1 | $0 |
| Net Income | $3 | $3 | $4 | $3 |
| % Margin | 18% | 20% | 29% | 32.9% |
| EPS | 0.82 | 0.81 | 1.06 | 0.81 |
| % Growth | 1.2% | -23.6% | 30.9% | – |
| EPS Diluted | 0.78 | 0.77 | 1.01 | 0.77 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | $6 | $6 | $6 | $5 |
| % Margin | 34.4% | 32.3% | 40.8% | 43.9% |